Q2 2018 EPS Estimates for Boston Scientific Corporation (BSX) Reduced by Analyst

Boston Scientific Corporation (NYSE:BSX) – Leerink Swann dropped their Q2 2018 earnings per share estimates for shares of Boston Scientific in a note issued to investors on Thursday. Leerink Swann analyst D. Antalffy now anticipates that the medical equipment provider will post earnings of $0.35 per share for the quarter, down from their prior estimate of $0.37. Leerink Swann also issued estimates for Boston Scientific’s Q3 2018 earnings at $0.34 EPS, Q4 2018 earnings at $0.37 EPS, FY2018 earnings at $1.37 EPS, FY2019 earnings at $1.56 EPS and FY2020 earnings at $1.75 EPS.

BSX has been the subject of several other research reports. SunTrust Banks set a $34.00 target price on shares of Boston Scientific and gave the company a “buy” rating in a research note on Tuesday, October 31st. Zacks Investment Research downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. BMO Capital Markets reaffirmed a “buy” rating and issued a $32.00 target price on shares of Boston Scientific in a research note on Tuesday, December 12th. Evercore ISI began coverage on shares of Boston Scientific in a research note on Wednesday, January 3rd. They issued an “in-line” rating and a $27.00 target price for the company. Finally, Jefferies Group reaffirmed a “neutral” rating on shares of Boston Scientific in a research note on Friday. One analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $31.00.

Shares of Boston Scientific (BSX) opened at $27.39 on Monday. Boston Scientific has a 12 month low of $23.29 and a 12 month high of $29.93. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58. The company has a market cap of $37,610.00, a P/E ratio of 391.29, a price-to-earnings-growth ratio of 1.96 and a beta of 0.81.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.34. The business had revenue of $2.41 billion during the quarter, compared to the consensus estimate of $2.39 billion. Boston Scientific had a net margin of 1.15% and a return on equity of 24.04%. Boston Scientific’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.30 earnings per share.

In other Boston Scientific news, EVP Michael P. Phalen sold 15,835 shares of the stock in a transaction on Friday, December 29th. The shares were sold at an average price of $25.25, for a total value of $399,833.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Valley Gold Master Fund L. Sun purchased 408,006 shares of the business’s stock in a transaction on Tuesday, November 28th. The stock was purchased at an average price of $0.45 per share, with a total value of $183,602.70. Insiders have sold 76,237 shares of company stock valued at $1,996,806 in the last 90 days. 0.74% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in the business. Meeder Asset Management Inc. bought a new position in shares of Boston Scientific in the fourth quarter valued at about $293,000. Public Employees Retirement Association of Colorado raised its position in shares of Boston Scientific by 3.5% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 260,082 shares of the medical equipment provider’s stock valued at $6,447,000 after purchasing an additional 8,727 shares during the period. CIBC Asset Management Inc raised its position in shares of Boston Scientific by 5.1% in the fourth quarter. CIBC Asset Management Inc now owns 139,928 shares of the medical equipment provider’s stock valued at $3,469,000 after purchasing an additional 6,751 shares during the period. Aperio Group LLC raised its position in shares of Boston Scientific by 0.5% in the fourth quarter. Aperio Group LLC now owns 519,407 shares of the medical equipment provider’s stock valued at $12,876,000 after purchasing an additional 2,830 shares during the period. Finally, Comerica Bank raised its position in shares of Boston Scientific by 1.9% in the fourth quarter. Comerica Bank now owns 365,319 shares of the medical equipment provider’s stock valued at $10,196,000 after purchasing an additional 6,810 shares during the period. Hedge funds and other institutional investors own 90.59% of the company’s stock.

WARNING: “Q2 2018 EPS Estimates for Boston Scientific Corporation (BSX) Reduced by Analyst” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/05/q2-2018-eps-estimates-for-boston-scientific-corporation-bsx-reduced-by-analyst.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Earnings History and Estimates for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply